A Phase I/IIa Dose Escalation Study in Asia of Repeated Administration of "CYT107" (glyco-r-hIL-7) Add On Treatment in Genotype 1 HCV Infected Patients Resistant To Pegylated Interferon-Alpha and Ribavirin.
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Interleukin-7; Peginterferon alfa; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions
- Acronyms ECLIPSE-3
- Sponsors Revimmune SAS
- 17 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 17 Oct 2012 Planned End Date changed from 1 Jun 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 06 Dec 2009 Additional lead trial centres and investigators identified as reported by ClinicalTrials.gov.